GlassScriptPhysician profile
Nicole Maddox
NPI 1093276156
$1,795.06
in general payments reported to CMS, 2019-2025
26 companies · $411 in 2025
The $411 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.97 · 2022: $260 · 2023: $520 · 2024: $578 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,311 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,310.64 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $309.70 | 2023-2025 | Jakafi, Monjuvi |
| Amgen INC. | $236.84 | 2022 | |
| Novartis Pharmaceuticals Corporation | $194.86 | 2023-2025 | |
| Glaxosmithkline, LLC. | $156.63 | 2024-2025 | Jemperli |
| Janssen Biotech, INC. | $111.06 | 2024-2025 | Balversa, Akeega, Erleada |
| Abbvie INC. | $104.94 | 2023-2025 | |
| Exeltis, USA INC. | $84.87 | 2022-2023 | Slynd |
| Seagen INC. | $78.15 | 2023 | Tivdak, Adcetris |
| Takeda Pharmaceuticals U.S.A., INC. | $73.57 | 2023-2025 | Fruzaqla, Ninlaro |
| Bayer Healthcare Pharmaceuticals INC. | $60.61 | 2024-2025 | |
| Daiichi Sankyo INC. | $50.01 | 2024 | Enhertu |
| Regeneron Healthcare Solutions, INC. | $49.84 | 2023-2024 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $40.06 | 2024 | Lynparza, Imfinzi |
| Bioprotect Medical, INC. | $29.69 | 2025 | Bioprotect Balloon Implant System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.01 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $23.43 | 2025 | Orserdu |
| Sun Pharmaceutical Industries INC. | $21.40 | 2024 | |
| Merck Sharp & Dohme LLC | $20.93 | 2023 | Lynparza, Keytruda, Welireg |
| Alexion Pharmaceuticals, INC. | $19.63 | 2024 | Ultomiris |
| Lilly USA, LLC | $17.13 | 2025 | Verzenio, Retevmo, Jaypirca |
| Sobi, INC | $17.10 | 2023 | |
| Sumitomo Pharma America, INC. | $15.69 | 2023 | Orgovyx |
| Mirati Therapeutics, INC. | $14.59 | 2023 | Krazati |
| Eisai INC. | $13.35 | 2024 | |
| Amarin Pharma, INC. | $12.95 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Maddox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.